Key Responsibilities

Therapeutic Area Leadership & Strategy

• Advance clinical programs across Cardiorenal disorders, and associated

chronic disease pathways, integrating parenteral and pulmonary drug

delivery strategies where relevant.

• Serve as the senior clinical authority for Cardiorenal drug development,

representing the therapeutic area across executive, governance, and

strategic decision‑making forums.

• Synthesize scientific, clinical, regulatory, and competitive insights to guide

pipeline prioritization, shape evidence strategies, and inform long‑range

portfolio and lifecycle planning.

• (Define and) Partner with the CMO to lead the clinical development strategy

for the heart failure portfolio, ensuring alignment with scientific

platforms, inhaled‑therapeutic technologies, and long‑term enterprise

objectives.

Clinical Study Planning & Design

• Lead the design and planning of Phase 1–4 clinical trials across cardiorenal and

related chronic disease indications, including dose selection, patient

segmentation, biomarker strategy, and endpoint development.

• Engage internal scientific leaders and external experts across cardiology,

nephrology, critical care, and related specialties to refine study rationale,

strengthen mechanistic understanding, and optimize development pathways.

• Oversee advisory board strategy and insight generation to integrate

cross‑disciplinary perspectives and ensure study designs reflect real‑world clinical

practice and unmet need.

• Ensure clinical protocols meet the highest standards of scientific integrity,

operational feasibility, and regulatory alignment, supporting efficient execution

and high‑quality evidence generation.

Clinical Study Execution & Oversight

• Oversee the execution of all Cardiorenal clinical programs, directing

cross‑functional interfaces to ensure robust, efficient, and high‑quality delivery of

evidence across early‑ and late‑stage development.

• Biostatistics & Data Management – Partner closely to ensure data integrity,

statistical rigor, and high‑quality analyses that support regulatory submissions and

scientific decision‑making.